To determine the genome‐wide distribution of ZEB1‐binding regions in MDA‐231‐D and Hs578T basal‐type breast cancer cells, we performed ChIP‐seq analysis using a validated ZEB1 antibody that did not cross‐react with ZEB2 (Fig. S1A; Horiguchi et al., 2012). This evidence concerns the gene ZEB2 and breast carcinoma.